# Medical-device reimbursement listing
Consultancies that secure CPT/HCPCS billing codes, payer coverage policies and national health-insurance listings for medical devices — turning FDA clearance into an actual reimbursement pathway that determines whether hospitals and clinicians will be paid to use the device.
Source: https://en.bioecon.ru/technology/medical-device-reimbursement-listing/
Updated: 2026-08-18
## Overview and value chain
Markers: [EC: Medical-device coding, coverage & reimbursement listing services | OECD: Bioeconomy policy & governance | Regulator: FDA (US)]
Medical-device reimbursement listing is a B2B services category in which specialist consultancies secure the CPT/HCPCS billing codes, payer coverage policies and national health-insurance listings a medical device needs to be paid for in clinical use — a step distinct from, and often more commercially decisive than, FDA clearance itself. MCRA runs a dedicated regulatory and reimbursement consulting practice supporting medical device companies through both FDA 510(k) submission and CPT/HCPCS coding strategy. Avalere Health integrates clinical, coding and reimbursement strategy from early development, arguing that early-integrated strategies transform market-access challenges into successful launches with clear coverage and payment pathways. Boston Strategic Partners combines business and clinical strategy with health-economics and outcomes research (HEOR) and medical/technical writing to support device reimbursement dossiers. Emergo by UL, a global QA/RA consulting firm, extends its FDA 510(k)/De Novo/PMA regulatory practice into the reimbursement-adjacent compliance work devices need alongside clearance. Real Endpoints is a market-access advisory firm focused specifically on commercial and private-payer coverage policy and prior-authorization navigation for medical devices. Vintura, based in the Netherlands, advises life-sciences clients on policy shaping and commercial strategy across European reimbursement systems, addressing the persistent gap between what a device or medicine can offer and what patients actually receive.
The key directions of medical-device reimbursement listing are:
1. **CPT/HCPCS coding strategy:** securing or navigating the billing codes (Current Procedural Terminology, Healthcare Common Procedure Coding System) a device needs for a provider to bill for its use.
2. **Payer coverage-policy navigation:** working with commercial insurers and public payers to establish a coverage policy under which the device is eligible for payment.
3. **Health-economics and outcomes research (HEOR):** building the clinical and economic evidence dossier payers require to justify a coverage or reimbursement decision.
4. **European and national reimbursement-system policy shaping:** advising on the specific health-technology-assessment and reimbursement-listing processes of individual national systems outside the US.
### Sectoral value chain
```
[FDA clearance/approval] ──> [CPT/HCPCS coding strategy] ──> [Payer coverage-policy submission]
│
(HEOR evidence-dossier development)
│
[Ongoing coverage-policy monitoring] <──── [Reimbursement decision & listing] <─── [Payer review & negotiation]
```
### Value chain levels
| Level | Description | Key inputs/outputs |
|:---|:---|:---|
| **Regulatory clearance** | The device receives FDA clearance or approval, the prerequisite before a reimbursement pathway can be pursued. | **In:** Regulatory submission.
**Out:** Cleared/approved device. |
| **Coding strategy** | Determining and securing the CPT/HCPCS billing codes a provider needs to bill for the device's use. | **In:** Cleared/approved device, procedure description.
**Out:** Assigned or requested billing code. |
| **Coverage-policy submission** | Submitting evidence to commercial and public payers to establish a coverage policy for the device. | **In:** Billing code, clinical evidence.
**Out:** Coverage-policy submission. |
| **Payer review and negotiation** | Payers review the submission, often requesting additional health-economics evidence before deciding. | **In:** Coverage-policy submission.
**Out:** Payer review outcome. |
| **Reimbursement decision and listing** | The payer issues a coverage decision and, where applicable, the device is added to a formal reimbursement listing. | **In:** Payer review outcome.
**Out:** Coverage decision, reimbursement listing. |
| **Ongoing coverage-policy monitoring** | Tracking payer coverage-policy changes and prior-authorization requirements that affect the device's ongoing reimbursement status. | **In:** Reimbursement listing.
**Out:** Maintained reimbursement status. |
Cross-cutting technologies of the sector:
- **CPT/HCPCS coding strategy:** the specific process of determining and securing the billing codes a medical device needs for a provider to be paid for its use.
- **Payer coverage-policy analytics:** structured tracking and analysis of commercial and public payer coverage policies relevant to a specific device category.
- **Market-access consulting:** integrated advisory services combining regulatory, coding, coverage and HEOR expertise to build a full reimbursement pathway.
---
## US
The United States hosts the largest concentration of medical-device reimbursement consultancies, several combining FDA regulatory practices with dedicated coding and payer-coverage expertise.
### MCRA's combined regulatory-reimbursement practice, Avalere's integrated coding strategy, Boston Strategic Partners' HEOR support, Emergo by UL's global QA/RA-adjacent work, Real Endpoints' payer-coverage focus
- **MCRA:** runs a dedicated regulatory and reimbursement consulting practice supporting medical device companies through both FDA 510(k) submission and CPT/HCPCS coding strategy.
- **Avalere Health:** integrates clinical, coding and reimbursement strategy from early development, transforming market-access challenges into launches with clear coverage and payment pathways.
- **Boston Strategic Partners:** combines business and clinical strategy with health-economics and outcomes research and medical/technical writing to support device reimbursement dossiers.
- **Emergo by UL:** a global QA/RA consulting firm extending its FDA 510(k)/De Novo/PMA regulatory practice into the reimbursement-adjacent compliance work devices need alongside clearance.
- **Real Endpoints:** a market-access advisory firm focused specifically on commercial and private-payer coverage policy and prior-authorization navigation for medical devices.
---
## CN
China is covered qualitatively rather than through a live-screened Chinese vendor: candidate Chinese medical-device reimbursement consultancies searched during this screen returned no confirming 2026 source, so no Chinese company is tabled below. Medical-device reimbursement listing in China runs through the National Healthcare Security Administration's centralized procurement and medical-insurance catalog processes rather than the payer-by-payer model common in the US and Europe, and specialist consulting practices supporting this process could not be confirmed in this screen.
### China's centralized medical-insurance listing process without a confirmed specialist consultancy
- **Centralized listing model:** device reimbursement in China runs through the National Healthcare Security Administration's centralized procurement and medical-insurance catalog listing process, structurally distinct from the multi-payer US model.
- **Domestic gap:** no Chinese-headquartered medical-device reimbursement consultancy confirmed by a live 2026 source was found during this screen.
---
## EU
Europe hosts market-access and policy-shaping consultancies working across the fragmented national health-technology-assessment and reimbursement-listing systems of individual EU member states.
### Vintura's policy-shaping and commercial-strategy practice across European reimbursement systems
- **Vintura:** based in the Netherlands, advises life-sciences clients on policy shaping and commercial strategy across European reimbursement systems, addressing the persistent gap between what a device can offer and what patients actually receive under national coverage decisions.
---
## Leading companies and research institutes
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|:---|:---|:---|:---|:---|
| **MCRA** | 🇺🇸 USA | Regulatory + reimbursement consulting | Combined FDA 510(k) and CPT/HCPCS practice | commercial |
| **Avalere Health** | 🇺🇸 USA | Integrated market-access advisory | Clinical/coding/reimbursement strategy | commercial |
| **Boston Strategic Partners** | 🇺🇸 USA | Business & clinical strategy | HEOR and medical/technical writing | commercial |
| **Emergo by UL** | 🇺🇸 USA | Global QA/RA consulting | FDA 510(k)/De Novo/PMA-adjacent reimbursement work | commercial |
| **Real Endpoints** | 🇺🇸 USA | Payer-coverage advisory | Commercial/private-payer coverage focus | commercial |
| **Vintura** | 🇳🇱 Netherlands | European market-access consulting | Policy shaping across EU reimbursement systems | commercial |
---
## Tech stack and innovations
The medical-device reimbursement listing stack combines regulatory-adjacent coding expertise with structured payer-coverage analytics and health-economics evidence development:
1. **CPT/HCPCS coding strategy:**
- Firms such as MCRA and Avalere Health determine and secure the specific billing codes a device needs, a step that directly determines whether providers can be paid for using it.
2. **Payer coverage-policy analytics:**
- Real Endpoints specializes in tracking and navigating commercial and private-payer coverage policy and prior-authorization requirements specific to a device category.
3. **HEOR evidence development:**
- Boston Strategic Partners builds the health-economics and outcomes research evidence dossier payers require to justify a coverage or reimbursement decision.
---
## Value chains and production pipelines
### Industrial pipeline for a medical-device reimbursement listing engagement
```
┌───────────────────────────┐ ┌───────────────────────────┐
│ 1. Regulatory clearance │ ───> │ 2. CPT/HCPCS coding │
│ │ │ strategy │
└───────────────────────────┘ └───────────────────────────┘
│
▼
┌───────────────────────────┐ ┌───────────────────────────┐
│ 4. Payer review & │ <─── │ 3. Coverage-policy │
│ negotiation │ │ submission │
└───────────────────────────┘ └───────────────────────────┘
│
▼
┌───────────────────────────┐ ┌───────────────────────────┐
│ 5. Reimbursement decision │ ───> │ 6. Ongoing coverage- │
│ & listing │ │ policy monitoring │
└───────────────────────────┘ └───────────────────────────┘
```
#### Stage 1: Regulatory clearance
The device receives FDA clearance or approval, the prerequisite step before a reimbursement pathway can be pursued.
#### Stage 2: CPT/HCPCS coding strategy
The consultancy determines and secures the billing codes a provider needs to bill for the device's use, requesting a new code where none exists.
#### Stage 3: Coverage-policy submission
Evidence supporting the device's clinical and economic value is submitted to commercial and public payers to establish a formal coverage policy.
#### Stage 4: Payer review and negotiation
Payers review the submission, often requesting additional health-economics evidence or negotiating specific coverage terms before deciding.
#### Stage 5: Reimbursement decision and listing
The payer issues a coverage decision, and where applicable, the device is added to a formal reimbursement listing that providers can bill against.
#### Stage 6: Ongoing coverage-policy monitoring
The consultancy tracks payer coverage-policy changes and prior-authorization requirements that could affect the device's ongoing reimbursement status.